Active name: Elacestrant dihydrochloride Brand name: Orserdu Innovator name STEMLINE THERAPEUTICS INC Approval Date: Jan 27, 2023 Therapeutic activity: Elacestrant is an estrogen receptor antagonist used to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy Route of adminstration Tablet, oral Structure […]
API Flash News
Tag: estrogen receptor degrader (SERD)
Back To Top